Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
about
The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladderMirabegron in overactive bladder patients: efficacy review and update on drug safetyCUA guideline on adult overactive bladderEfficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.Postmenopausal overactive bladderActions of cAMP on calcium sensitization in human detrusor smooth muscle contraction.The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.A1 Adenosine Receptor-Mediated Inhibition of Parasympathetic Neuromuscular Transmission in Human and Murine Urinary BladderMirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockadeOveractive bladder - 18 years - Part IIProfile of mirabegron in the treatment of overactive bladder: place in therapy.Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms.Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.Delivery methods for drugs used in the treatment of overactive bladder.OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.A drug safety evaluation of mirabegron in the management of overactive bladder.Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist, in Human Liver Microsomes.Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study).Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder Aged ≥75 Years: Analysis of a Japanese Post-Marketing Study.Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury.Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.
P2860
Q26770419-1E7D1563-6B93-4CEC-A6DD-EB8A7AC9F373Q28072230-C5A825F2-AC15-4CA4-A9A6-7F27B5160AFCQ33665026-B961C498-62E9-4DF9-A17E-4417E4705A4BQ33727733-92309518-29F1-4C83-87BC-46829CDFF4C0Q35157329-B20BBA55-FF4D-41F7-BEDF-C069A3ED8CCBQ35633710-FC96E645-55DC-475F-87BC-CAA9EE6793B5Q36086072-D947B1E0-0E5F-4ABC-9B4A-9E97992A54A4Q36089975-FBDA8D00-D441-48C0-9DB7-D917426CAFB6Q36432305-8B62E12F-7972-44BA-B1F6-BB3805C37243Q36506889-175826C4-6B1F-416A-8CAC-5458E9F444C0Q36912766-58CCF963-99E5-4DF3-9A7A-714027421111Q37664787-92B38323-DD84-4AF8-9CFD-865511F56884Q38193896-77418932-05EB-4D45-8217-16744A95E5E4Q38262087-9A1A1A13-EB51-4F47-82BC-CE63A57B98F2Q38577301-9EAD06B2-8DA2-4BFC-990D-DC3D5CF1448CQ38612038-C2E071FD-53FF-4C0E-A0B5-B5889E37A019Q38649685-0BB60CBF-1D8E-4F3C-B895-F99583C9B60AQ38665319-88D9282C-1319-4BD5-B40B-3E76B042E8EAQ38669033-96E11640-7AF6-40CA-9BA4-3CE11DDB0EA0Q38765381-E1BB4CA2-9F0D-4F15-80FB-AF9F596A2B66Q38776115-1ED367F6-1FE0-4734-964A-A800408B0F45Q38993756-9C3D799F-0256-4AE5-B853-730C353B31C7Q39046374-D681A4E2-314E-4B5C-BB68-80891BB4F59FQ39176604-3D57F44C-4072-4704-AAF9-A9B0B75ADAE2Q43928336-140D6763-1FC9-4D2F-80CF-E56E13BB50CAQ47375147-94B9CA23-8408-4721-80DB-1D3AA0248A72Q47433658-AA5696B6-7AAD-465B-8D18-6EECE01ED517Q47585163-312509D2-ED1B-401F-AFB4-22649B6EB136Q47704193-FA85DDBC-B6D2-44D8-8CD3-1412E9BB9A36Q47784907-93F08930-ADF9-447B-AFBF-7F509F94B156Q47991589-987AE087-B728-4110-B264-30F8B641A7BDQ47993403-90AE2586-070F-47A0-820A-CEB63193B377Q48719101-C3369FD9-FC74-4BF1-BC86-36DE334AECD1Q48795592-079D1C3F-7B96-4C53-9A01-AC095DA10236Q49243698-8A5C8D3B-B838-428B-85C2-6562C529A393Q50073415-BBEC83F1-F0FB-4323-86A6-A910EF265D74Q50881211-B02338E3-72D8-4D98-8EDC-EEA19589084CQ50890665-BCA0EB05-F628-4C42-A44E-6D84AA864FF2Q55429410-AEDF9767-425A-4945-94C3-11DEC09AAC56
P2860
Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Phase III, randomised, double- ...... ients with overactive bladder.
@en
Phase III, randomised, double- ...... ients with overactive bladder.
@nl
type
label
Phase III, randomised, double- ...... ients with overactive bladder.
@en
Phase III, randomised, double- ...... ients with overactive bladder.
@nl
prefLabel
Phase III, randomised, double- ...... ients with overactive bladder.
@en
Phase III, randomised, double- ...... ients with overactive bladder.
@nl
P2093
P2860
P356
P1433
P1476
Phase III, randomised, double- ...... ients with overactive bladder.
@en
P2093
Eiji Marui
Hidehiro Kakizaki
Masaki Yoshida
Masayuki Takeda
Momokazu Gotoh
Narihito Seki
Osamu Nishizawa
Osamu Yamaguchi
Osamu Yokoyama
Sumito Ohkawa
P2860
P304
P356
10.1111/BJU.12649
P577
2014-03-17T00:00:00Z